RESUMEN
BACKGROUND: Indirect neonatal hyperbilirubinemia (INH) is a common neonatal disorder worldwide which can remain benign if prompt management is available. However there is a higher morbidity and mortality risk in settings with limited access to diagnosis and care. The manuscript describes the characteristics of neonates with INH, the burden of severe INH and identifies factors associated with severity in a resource-constrained setting. METHODS: We conducted a retrospective evaluation of anonymized records of neonates hospitalized on the Thai-Myanmar border. INH was defined according to the National Institute for Health and Care Excellence guidelines as 'moderate' if at least one serum bilirubin (SBR) value exceeded the phototherapy threshold and as 'severe' if above the exchange transfusion threshold. RESULTS: Out of 2980 records reviewed, 1580 (53%) had INH within the first 14 days of life. INH was moderate in 87% (1368/1580) and severe in 13% (212/1580). From 2009 to 2011, the proportion of severe INH decreased from 37 to 15% and the mortality dropped from 10% (8/82) to 2% (7/449) coinciding with the implementation of standardized guidelines and light-emitting diode (LED) phototherapy. Severe INH was associated with: prematurity (< 32 weeks, Adjusted Odds Ratio (AOR) 3.3; 95% CI 1.6-6.6 and 32 to 37 weeks, AOR 2.2; 95% CI 1.6-3.1), Glucose-6-phosphate dehydrogenase deficiency (G6PD) (AOR 2.3; 95% CI 1.6-3.3), potential ABO incompatibility (AOR 1.5; 95% CI 1.0-2.2) and late presentation (AOR 1.8; 95% CI 1.3-2.6). The risk of developing severe INH and INH-related mortality significantly increased with each additional risk factor. CONCLUSION: INH is an important cause of neonatal hospitalization on the Thai-Myanmar border. Risk factors for severity were similar to previous reports from Asia. Implementing standardized guidelines and appropriate treatment was successful in reducing mortality and severity. Accessing to basic neonatal care including SBR testing, LED phototherapy and G6PD screening can contribute to improve neonatal outcomes.
Asunto(s)
Hiperbilirrubinemia Neonatal/epidemiología , Sistema del Grupo Sanguíneo ABO , Incompatibilidad de Grupos Sanguíneos/complicaciones , Deficiencia de Glucosafosfato Deshidrogenasa/complicaciones , Hospitalización , Humanos , Hiperbilirrubinemia Neonatal/complicaciones , Hiperbilirrubinemia Neonatal/mortalidad , Hiperbilirrubinemia Neonatal/terapia , Recién Nacido , Enfermedades del Prematuro/epidemiología , Enfermedades del Prematuro/mortalidad , Enfermedades del Prematuro/terapia , Mianmar/epidemiología , Fototerapia , Estudios Retrospectivos , Factores de Riesgo , Tailandia/epidemiologíaRESUMEN
The structure-based design, chemical synthesis, and biological evaluation of various ketomethylene-containing human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds are comprised of a peptidomimetic binding determinant and an ethyl propenoate Michael acceptor moiety which forms an irreversible covalent adduct with the active site cysteine residue of the 3C enzyme. The ketomethylene-containing inhibitors typically display slightly reduced 3CP inhibition activity relative to the corresponding peptide-derived molecules, but they also exhibit significantly improved antiviral properties. Optimization of the ketomethylene-containing compounds is shown to provide several highly active 3C protease inhibitors which function as potent antirhinoviral agents (EC90 = <1 microM) against multiple virus serotypes in cell culture.
Asunto(s)
Antivirales/síntesis química , Cisteína Endopeptidasas/metabolismo , Inhibidores de Cisteína Proteinasa/síntesis química , Dipéptidos/síntesis química , Cetonas/síntesis química , Rhinovirus/enzimología , Proteínas Virales , Proteasas Virales 3C , Antivirales/química , Antivirales/farmacología , Línea Celular , Inhibidores de Cisteína Proteinasa/química , Inhibidores de Cisteína Proteinasa/farmacología , Dipéptidos/química , Dipéptidos/farmacología , Diseño de Fármacos , Humanos , Cetonas/química , Cetonas/farmacología , Imitación Molecular , Rhinovirus/efectos de los fármacos , Relación Estructura-ActividadRESUMEN
The structure-based design and subsequent chemical synthesis of novel, urea-containing FKBP12 inhibitors are described. These compounds are shown to disrupt the cis-trans peptidylprolyl isomerase activity of FKBP12 with inhibition constants (Ki,app) approaching 0.10 microM. Analyses of several X-ray crystal structures of FKBP12-urea complexes demonstrate that the urea-containing inhibitors associate with FKBP12 in a manner that is similar to, but significantly different from, that observed for the natural product FK506.
Asunto(s)
Proteínas Portadoras/antagonistas & inhibidores , Proteínas de Unión al ADN/antagonistas & inhibidores , Diseño de Fármacos , Proteínas de Choque Térmico/antagonistas & inhibidores , Urea/análisis , Isomerasas de Aminoácido/antagonistas & inhibidores , Secuencia de Aminoácidos , Proteínas Portadoras/química , Cristalografía por Rayos X , Proteínas de Unión al ADN/química , Proteínas de Choque Térmico/química , Humanos , Espectroscopía de Resonancia Magnética , Datos de Secuencia Molecular , Isomerasa de Peptidilprolil , Relación Estructura-Actividad , Tacrolimus/química , Proteínas de Unión a TacrolimusRESUMEN
The structure-based design, chemical synthesis, and biological evaluation of peptide-derived human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds incorporate various Michael acceptor moieties and are shown to irreversibly bind to HRV serotype 14 3CP with inhibition activities (kobs/[I]) ranging from 100 to 600 000 M-1 s-1. These inhibitors are also shown to exhibit antiviral activity when tested against HRV-14-infected H1-HeLa cells with EC50's approaching 0.50 microM. Extensive structure-activity relationships developed by Michael acceptor alteration are reported along with the evaluation of several compounds against HRV serotypes other than 14. A 2.0 A crystal structure of a peptide-derived inhibitor complexed with HRV-2 3CP is also detailed.
Asunto(s)
Antivirales , Cisteína Endopeptidasas/metabolismo , Inhibidores de Cisteína Proteinasa , Diseño de Fármacos , Oligopéptidos , Rhinovirus/efectos de los fármacos , Proteínas Virales , Proteasas Virales 3C , Animales , Antivirales/síntesis química , Antivirales/química , Antivirales/metabolismo , Antivirales/farmacología , Sitios de Unión , Línea Celular Transformada , Cristalografía por Rayos X , Cisteína Endopeptidasas/química , Inhibidores de Cisteína Proteinasa/síntesis química , Inhibidores de Cisteína Proteinasa/química , Inhibidores de Cisteína Proteinasa/metabolismo , Inhibidores de Cisteína Proteinasa/farmacología , Estabilidad de Medicamentos , Células HeLa , Humanos , Oligopéptidos/síntesis química , Oligopéptidos/química , Oligopéptidos/metabolismo , Oligopéptidos/farmacología , Conformación Proteica , Ratas , Ratas Sprague-Dawley , Rhinovirus/enzimología , Relación Estructura-ActividadRESUMEN
The structure-based design, chemical synthesis, and biological evaluation of various peptide-derived human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds are comprised of an ethyl propenoate Michael acceptor moiety and a tripeptidyl binding determinant. The systematic modification of each amino acid residue present in the binding determinant as well as the N-terminal functionality is described. Such modifications are shown to provide irreversible HRV-14 3CP inhibitors with anti-3CP activities (kobs/[I]) ranging from 60 to 280 000 M-1 s-1 and antiviral EC50's which approach 0.15 microM. An optimized inhibitor which incorporates several improvements identified by the structure-activity studies is also described. This molecule displays very rapid irreversible inhibition of HRV-14 3CP (kobs/[I] = 800 000 M-1 s-1) and potent antiviral activity against HRV-14 in cell culture (EC50 = 0.056 microM). A 1.9 A crystal structure of an S-alkylthiocarbamate-containing inhibitor complexed with HRV-2 3CP is also detailed.
Asunto(s)
Antivirales , Cisteína Endopeptidasas/metabolismo , Inhibidores de Cisteína Proteinasa , Diseño de Fármacos , Oligopéptidos , Rhinovirus/efectos de los fármacos , Proteínas Virales , Proteasas Virales 3C , Antivirales/síntesis química , Antivirales/química , Antivirales/metabolismo , Antivirales/farmacología , Sitios de Unión , Línea Celular Transformada , Cristalografía por Rayos X , Cisteína Endopeptidasas/química , Inhibidores de Cisteína Proteinasa/síntesis química , Inhibidores de Cisteína Proteinasa/química , Inhibidores de Cisteína Proteinasa/metabolismo , Inhibidores de Cisteína Proteinasa/farmacología , Evaluación Preclínica de Medicamentos , Humanos , Oligopéptidos/síntesis química , Oligopéptidos/química , Oligopéptidos/metabolismo , Oligopéptidos/farmacología , Rhinovirus/enzimología , Relación Estructura-ActividadRESUMEN
The structure-based design, chemical synthesis, and biological evaluation of various human rhinovirus (HRV) 3C protease (3CP) inhibitors which incorporate P1 lactam moieties in lieu of an L-glutamine residue are described. These compounds are comprised of a tripeptidyl or peptidomimetic binding determinant and an ethyl propenoate Michael acceptor moiety which forms an irreversible covalent adduct with the active site cysteine residue of the 3C enzyme. The P1-lactam-containing inhibitors display significantly increased 3CP inhibition activity along with improved antirhinoviral properties relative to corresponding L-glutamine-derived molecules. In addition, several lactam-containing compounds exhibit excellent selectivity for HRV 3CP over several other serine and cysteine proteases and are not appreciably degraded by a variety of biological agents. One of the most potent inhibitors (AG7088, mean antirhinoviral EC90 approximately 0.10 microM, n = 46 serotypes) is shown to warrant additional preclinical development to explore its potential for use as an antirhinoviral agent.
Asunto(s)
Antivirales/síntesis química , Cisteína Endopeptidasas/metabolismo , Inhibidores de Cisteína Proteinasa/síntesis química , Glutamina/química , Isoxazoles/síntesis química , Lactamas/síntesis química , Oligopéptidos/síntesis química , Pirrolidinonas/síntesis química , Rhinovirus/enzimología , Proteínas Virales , Proteasas Virales 3C , Antivirales/química , Antivirales/farmacología , Línea Celular , Cristalografía por Rayos X , Inhibidores de Cisteína Proteinasa/química , Inhibidores de Cisteína Proteinasa/farmacología , Diseño de Fármacos , Evaluación Preclínica de Medicamentos , Humanos , Isoxazoles/química , Isoxazoles/farmacología , Lactamas/química , Lactamas/farmacología , Modelos Moleculares , Imitación Molecular , Oligopéptidos/química , Oligopéptidos/farmacología , Fenilalanina/análogos & derivados , Pirrolidinonas/química , Pirrolidinonas/farmacología , Rhinovirus/efectos de los fármacos , Relación Estructura-Actividad , Valina/análogos & derivadosRESUMEN
Symptom severity in patients with human rhinovirus (HRV)-induced respiratory illness is associated with elevated levels of the inflammatory cytokines interleukin-6 (IL-6) and IL-8. AG7088 is a novel, irreversible inhibitor of the HRV 3C protease. In this study, AG7088 was tested for its antiviral activity and ability to inhibit the production of IL-6 and IL-8 in a human bronchial epithelial cell line, BEAS-2B. Infection of BEAS-2B cells with HRV 14 resulted in the production of both infectious virus and the cytokines IL-6 and IL-8. Treatment of HRV 14-infected cells with AG7088 resulted in a statistically significant (P, <0.05) dose-dependent reduction in the levels of infectious virus as well as IL-6 and IL-8 released into the cell supernatant compared to the results obtained for compound-free infected cells. AG7088 was also able to inhibit the replication of HRV 2 and 16 in BEAS-2B cells. In time-of-addition studies, AG7088 could be added as late as 14 to 26 h after HRV 14 infection of BEAS-2B cells and still result in a statistically significant (P, <0.05) reduction in the levels of infectious virus, IL-6, and IL-8 compared to the results obtained for compound-free infected cells. These findings have implications for the development of an antirhinovirus agent that may not only block virus replication but also diminish symptoms.
Asunto(s)
Antivirales/farmacología , Cisteína Endopeptidasas/metabolismo , Inhibidores de Cisteína Proteinasa/farmacología , Citocinas/metabolismo , Isoxazoles/farmacología , Pirrolidinonas/farmacología , Rhinovirus/efectos de los fármacos , Proteínas Virales , Proteasas Virales 3C , Células Cultivadas , Cisteína Endopeptidasas/efectos de los fármacos , Citocinas/antagonistas & inhibidores , Células HeLa , Humanos , Pruebas de Sensibilidad Microbiana , Fenilalanina/análogos & derivados , Rhinovirus/enzimología , Rhinovirus/metabolismo , Factores de Tiempo , Valina/análogos & derivadosRESUMEN
Novel tripeptidyl C-terminal Michael acceptors with an ester replacement of the P(2)-P(3) amide bond were investigated as irreversible inhibitors of the human rhinovirus (HRV) 3C protease (3CP). When screened against HRV serotype-14 the best compound was shown to have very good 3CP inhibition (k(obs)/[I]=270,000M(-1)s(-1)) and potent in vitro antiviral activity (EC(50)=7.0nM).
Asunto(s)
Péptidos/síntesis química , Inhibidores de Proteasas/síntesis química , Proteínas Virales/antagonistas & inhibidores , Proteasas Virales 3C , Antivirales/síntesis química , Antivirales/química , Antivirales/farmacología , Cisteína Endopeptidasas/metabolismo , Pruebas de Sensibilidad Microbiana , Modelos Moleculares , Péptidos/química , Péptidos/farmacología , Inhibidores de Proteasas/química , Inhibidores de Proteasas/farmacología , Rhinovirus/efectos de los fármacos , Relación Estructura-Actividad , Proteínas Virales/metabolismoRESUMEN
Tripeptide-derived molecules incorporating C-terminal ketone electrophiles were evaluated as reversible inhibitors of the cysteine-containing human rhinovirus 3C protease (3CP). An optimized example of such compounds displayed potent 3CP inhibition activity (K = 0.0045 microM) and in vitro antiviral properties (EC50=0.34 microM) when tested against HRV serotype-14.
Asunto(s)
Antivirales/síntesis química , Cisteína Endopeptidasas/metabolismo , Inhibidores de Cisteína Proteinasa/síntesis química , Cetonas/síntesis química , Oligopéptidos/síntesis química , Rhinovirus/enzimología , Proteínas Virales , Proteasas Virales 3C , Antivirales/farmacología , Células Cultivadas , Inhibidores de Cisteína Proteinasa/farmacología , Diseño de Fármacos , Humanos , Concentración 50 Inhibidora , Cetonas/farmacología , Cinética , Oligopéptidos/farmacología , Rhinovirus/efectos de los fármacos , Relación Estructura-ActividadRESUMEN
AG7088 is a potent, irreversible inhibitor of human rhinovirus (HRV) 3C protease (inactivation rate constant (k(obs)/[I]) = 1,470,000 +/- 440,000 M(-1) s(-1) for HRV 14) that was discovered by protein structure-based drug design methodologies. In H1-HeLa and MRC-5 cell protection assays, AG7088 inhibited the replication of all HRV serotypes (48 of 48) tested with a mean 50% effective concentration (EC(50)) of 0.023 microM (range, 0.003 to 0.081 microM) and a mean EC(90) of 0.082 microM (range, 0.018 to 0.261 microM) as well as that of related picornaviruses including coxsackieviruses A21 and B3, enterovirus 70, and echovirus 11. No significant reductions in the antiviral activity of AG7088 were observed when assays were performed in the presence of alpha(1)-acid glycoprotein or mucin, proteins present in nasal secretions. The 50% cytotoxic concentration of AG7088 was >1,000 microM, yielding a therapeutic index of >12,346 to >333,333. In a single-cycle, time-of-addition assay, AG7088 demonstrated antiviral activity when added up to 6 h after infection. In contrast, a compound targeting viral attachment and/or uncoating was effective only when added at the initiation of virus infection. Direct inhibition of 3C proteolytic activity in infected cells treated with AG7088 was demonstrated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of radiolabeled proteins, which showed a dose-dependent accumulation of viral precursor polyproteins and reduction of processed protein products. The broad spectrum of antiviral activity of AG7088, combined with its efficacy even when added late in the virus life cycle, highlights the advantages of 3C protease as a target and suggests that AG7088 will be a promising clinical candidate.
Asunto(s)
Antivirales/farmacología , Cisteína Endopeptidasas/efectos de los fármacos , Isoxazoles/farmacología , Pirrolidinonas/farmacología , Rhinovirus/efectos de los fármacos , Proteínas Virales , Proteasas Virales 3C , División Celular/efectos de los fármacos , Cisteína Endopeptidasas/metabolismo , Inhibidores de Cisteína Proteinasa/farmacología , Células HeLa , Humanos , Pruebas de Sensibilidad Microbiana , Fenilalanina/análogos & derivados , Proteínas/farmacología , Rhinovirus/fisiología , Serotipificación , Valina/análogos & derivadosRESUMEN
Tripeptide-derived molecules incorporating N-methyl amino acid residues and C-terminal Michael acceptor moieties were evaluated as irreversible inhibitors of the cysteine-containing human rhinovirus 3C protease (3CP). Such compounds displayed good 3CP inhibition activity (k(obs)/[I] up to 610,000 M(-1) s(-1)) and potent in vitro antiviral properties (EC50 approaching 0.03 microM) when tested against HRV serotype-14.
Asunto(s)
Cisteína Endopeptidasas/metabolismo , Inhibidores de Proteasas/síntesis química , Rhinovirus/enzimología , Proteínas Virales , Proteasas Virales 3C , Cisteína Endopeptidasas/efectos de los fármacos , Diseño de Fármacos , Humanos , Péptidos/síntesis química , Péptidos/farmacología , Inhibidores de Proteasas/farmacología , Rhinovirus/efectos de los fármacos , Relación Estructura-ActividadRESUMEN
Human rhinoviruses, the most important etiologic agents of the common cold, are messenger-active single-stranded monocistronic RNA viruses that have evolved a highly complex cascade of proteolytic processing events to control viral gene expression and replication. Most maturation cleavages within the precursor polyprotein are mediated by rhinovirus 3C protease (or its immediate precursor, 3CD), a cysteine protease with a trypsin-like polypeptide fold. High-resolution crystal structures of the enzyme from three viral serotypes have been used for the design and elaboration of 3C protease inhibitors representing different structural and chemical classes. Inhibitors having alpha,beta-unsaturated carbonyl groups combined with peptidyl-binding elements specific for 3C protease undergo a Michael reaction mediated by nucleophilic addition of the enzyme's catalytic Cys-147, resulting in covalent-bond formation and irreversible inactivation of the viral protease. Direct inhibition of 3C proteolytic activity in virally infected cells treated with these compounds can be inferred from dose-dependent accumulations of viral precursor polyproteins as determined by SDS/PAGE analysis of radiolabeled proteins. Cocrystal-structure-assisted optimization of 3C-protease-directed Michael acceptors has yielded molecules having extremely rapid in vitro inactivation of the viral protease, potent antiviral activity against multiple rhinovirus serotypes and low cellular toxicity. Recently, one compound in this series, AG7088, has entered clinical trials.